Literature DB >> 9466020

Heparin and protamine titration do not improve haemostasis in cardiac surgical patients.

L Shore-Lesserson1, D L Reich, M DePerio.   

Abstract

PURPOSE: Weight-based heparin and protamine dosing strategies for cardiopulmonary bypass (CPB) do not take into account interpatient variability in drug sensitivity and may result in bleeding complications. We compared the Hemochron RxDx heparin and protamine titration system with standard weight based management with regard to heparin dose, protamine dose, and perioperative bleeding.
METHODS: One hundred and thirty-five cardiac surgical patients were randomised into four groups. Group 1 received standard heparin and protamine management: Group 2 received heparin and protamine by in vitro titration. Group 3 had the heparin dose titrated, and group 4 had the protamine dose titrated. Coagulation tests, bleeding, and transfusion requirements were measured.
RESULTS: The initial heparin bolus predicted by the titration was < 300 U.kg-1 in all patients. Group 2 received a lower heparin bolus for the initiation of bypass but total heparin doses were not different among groups (group 1 = 365 +/- 43, group 2 = 348 +/- 73 U.kg-1, group 3 = 394 +/- 86 U.kg-1, group 4 = 376 +/- 60; P = 0.06). Groups 2 and 4 received a lower initial and a lower total protamine dose (total dose group 1 = 4.03 +/- 0.65 mg.kg-1, group 2 = 3.56 +/- 1.11 mg.kg-1, group 3 = 4.22 +/- 0.90 mg.kg-1, group 4 = 3.38 +/- 0.98 mg.kg-1, P = 0.001). The incidences of incomplete heparin neutralisation (P = 0.14) and heparin rebound (P = 0.1) were not different among groups. Postoperative bleeding and transfusion requirements did not differ.
CONCLUSION: In cardiac surgical patients, heparin and protamine titration did predict a lower protamine dose but did not result in a measurable improvement in haemostasis during the perioperative period.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466020     DOI: 10.1007/BF03011985

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  7 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

Review 2.  Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures.

Authors:  H M Hussein; A L Georgiadis; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-15       Impact factor: 3.825

3.  Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery.

Authors:  Javier Suárez Cuenca; Pilar Gayoso Diz; Francisco Gude Sampedro; J Marcos Gómez Zincke; Helena Rey Acuña; M Manuela Fontanillo Fontanillo
Journal:  J Extra Corpor Technol       Date:  2013-12

4.  Blood management issues: getting clots together when you want them.

Authors:  Darryl McMillan; Kieron Potger; Joanne Southwell
Journal:  J Extra Corpor Technol       Date:  2011-03

5.  STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass.

Authors:  Linda Shore-Lesserson; Robert A Baker; Victor Ferraris; Philip E Greilich; David Fitzgerald; Philip Roman; John Hammon
Journal:  J Extra Corpor Technol       Date:  2018-03

6.  Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements.

Authors:  Sean Garvin; Daniel C FitzGerald; George Despotis; Prem Shekar; Simon C Body
Journal:  Anesth Analg       Date:  2009-10-27       Impact factor: 5.108

7.  Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study.

Authors:  Marx Runge; Christian H Møller; Daniel A Steinbrüchel
Journal:  J Extra Corpor Technol       Date:  2009-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.